🇺🇸 FDA
Patent

US 11976126

Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells

granted A61KA61K2039/505A61K39/39558

Quick answer

US patent 11976126 (Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells) held by Inhibrx, Inc. expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx, Inc.
Grant date
Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K39/39558, A61P, A61P35/00